BOSTON, August 13, 2025 — Leads & Copy — Aura Biosciences, Inc. (NASDAQ: AURA) reported its second quarter financial results and business highlights, focusing on clinical program execution in its Phase 3 CoMpass trial for early choroidal melanoma and its Phase 1b/2 trial for non-muscle invasive bladder cancer (NMIBC). The company strengthened its balance sheet with a $75 million equity financing and expects its cash position to fund operations into the first half of 2027.
CEO Elisabet de los Pinos, Ph.D., noted the focus on clinical program execution, including the global Phase 3 CoMpass trial and the Phase 1b/2 trial in NMIBC. She believes the company is well-positioned to advance the clinical development of bel-sar in ocular and urologic oncology programs, with the potential to impact patients’ lives meaningfully.
The CoMpass trial is actively enrolling globally, utilizing a pre-screening tool to identify patients with documented tumor growth. Over 240 patients have been registered in the pre-screening tool, indicating a need for vision-preserving therapy. Study enrollment may be completed as early as the end of 2025. Bel-sar is also in development for metastases to the choroid and cancers of the ocular surface, with a collective annual incidence of over 60,000 patients in the U.S. and Europe.
Aura Biosciences had $177.3 million in cash and cash equivalents and marketable securities as of June 30, 2025, sufficient to fund operations into the first half of 2027. Research and development expenses increased to $22.9 million for the three months ended June 30, 2025, from $16.9 million for the same period in 2024, due to clinical and CRO costs and manufacturing and development costs for bel-sar. The net loss for the three months ended June 30, 2025, was $27.0 million, compared to $20.3 million for the same period in 2024.
Alex Dasalla, Head of Investor Relations and Corporate Communications, can be reached at IR@aurabiosciences.com.
Source: Aura Biosciences
